Get this delivered to your inbox, and more info about our products and services.
Leerink upgrades Eli Lilly following landmark deal with U.S. government
Leerink Partners sees shares of Eli Lilly adding another 19% from here.
14 words~1 min read
Related reading
Bank of America hikes Eli Lilly price target on promising drug pipeline
Bank of America's new price target has shares of Eli Lilly climbing 22% from here.
We're raising our Eli Lilly price target — what a difference a quarter makes
The drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications
Eli Lilly earnings are coming Thursday. Here's what top analysts expect
Wall Street is optimistic heading into Eli Lilly's second-quarter earnings report.
Eli Lilly shares surge on a beat-and-raise, proving the stock's swoon was a…
Eli Lilly entered Thursday well off its highs. A blowout quarter shows the market got this one wrong.
Eli Lilly looks beyond its blockbuster obesity drugs with another smart deal
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge…
Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing…